cysteamine has been researched along with rasagiline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Badrinarayanan, S; Boivin, L; Bousquet, M; Chabrat, A; Charest, J; Cicchetti, F; Cisbani, G; Drouin-Ouellet, J; Gibrat, C; Lagacé, M; Lavallée-Bourget, MH; Lebel, M; Lévesque, M; Saint-Pierre, M | 1 |
1 review(s) available for cysteamine and rasagiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for cysteamine and rasagiline
| Article | Year |
|---|---|
Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Astrocytes; Cell Line; Cells, Cultured; Corpus Striatum; Cystamine; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Indans; Lipopolysaccharides; Male; Mice, Inbred C57BL; Neurites; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders | 2015 |